The new document focuses on the influence of PBMs over the market for specialty generic drugs for illnesses like cancer, ...

The pressure against pharmacy benefit managers (PBMs) continues to build. On Tuesday, the Federal Trade Commission released ...

The Federal Trade Commission (FTC) on Tuesday released its second interim report on pharmacy benefit managers (PBM), saying ...

The Arkansas Pharmacists Association is calling for public and legislative support for stronger regulation of Pharmacy ...

The Federal Trade Commission (“FTC”) released its second interim report on Jan. 14, 2025, accusing pharmacy benefit managers (PBMs) of marking up the prices of specialty generic drugs. FTC’s report ...

Pharmacy benefit managers, which serve as the middlemen between drug makers, insurers and pharmacies, reaped $7.3 billion in ...

Regulators published their most detailed findings yet on how some of the nation’s largest companies profited from "excess" ...

The Federal Trade Commision (FTC) found prescription benefits managers like UnitedHealth's OptumRX have gained $7.3B from ...

A report from the Federal Trade Commission (FTC) has determined that pharmacy benefit managers (PBMs) are linked to significant cost increases for cancer, HIV, and other critical specialty drugs.

Agency commissioners voted unanimously on Tuesday to publish the report, which makes similar allegations against the ...

For the second time in less than a year, the FTC has released a highly critical report of pharmacy benefit managers, or PBMs.

CVS Caremark, Express Scripts and OptumRx dramatically mark up specialty generic drugs to affiliated pharmacies, the Federal ...